European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift

被引:8
作者
Loustaud-Ratti, Veronique [1 ]
Debette-Gratien, Marilyne [1 ]
Carrier, Paul [1 ]
机构
[1] CHU Limoges, Serv Hepatogastroenterol, Federat Hepatol, 2 Ave Martin Luther King, F-87042 Limoges, France
关键词
French; European; Hepatitis C; Guidelines; Pangenotypic; Direct acting antiviral drugs; Eradication; People who inject drugs; Migrants;
D O I
10.4254/wjh.v10.i10.639
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The latest Association Francaise pour l'Etude du Foie - French Association for Study of the Liver (AFEF) and European Association for the Study of the Liver (EASL) recommendations announce a change of paradigm, for the management of patients infected with hepatitis C virus (HCV). The AFEF recommendations focus on the elimination of HCV infection on a national level by preventing reinfection, in less than ten years. This goal involves the facilitation of patients' management in a simplified pathway by increasing screening procedures and access to pangenotypic treatments mainly in the "reservoir" population of people who inject drugs and migrants. Even in the complex pathway of patients with previous comorbidities, AFEF takes the option of a therapeutic simplification. The EASL guidelines position themselves on the state of the art with a precise description of all therapeutic options available, without separating simplified and complex pathways even if they take into account the epidemiological evolution of difficult-to-treat populations. (c) The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:639 / 644
页数:6
相关论文
共 26 条
  • [1] Abergel A., 2017, AASLD ANN M 2017 OCT
  • [2] AFEF, REC TEXT OFF REC
  • [3] Pilot Study: Combining Formal and Peer Education with FibroScan to Increase HCV Screening and Treatment in Persons who use Drugs
    Arain, Amber
    De Sousa, Jessica
    Corten, Kirsten
    Verrando, Rita
    Thijs, Herbert
    Mathei, Catharina
    Buntinx, Frank
    Robaeys, Geert
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2016, 67 : 44 - 49
  • [4] Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
    Bourliere, M.
    Gordon, S. C.
    Flamm, S. L.
    Cooper, C. L.
    Ramji, A.
    Tong, M.
    Ravendhran, N.
    Vierling, J. M.
    Tran, T. T.
    Pianko, S.
    Bansal, M. B.
    Ledinghen, V. de
    Hyland, R. H.
    Stamm, L. M.
    Dvory-Sobol, H.
    Svarovskaia, E.
    Zhang, J.
    Huang, K. C.
    Subramanian, G. M.
    Brainard, D. M.
    McHutchison, J. G.
    Verna, E. C.
    Buggisch, P.
    Landis, C. S.
    Younes, Z. H.
    Curry, M. P.
    Strasser, S. I.
    Schiff, E. R.
    Reddy, K. R.
    Manns, M. P.
    Kowdley, K. V.
    Zeuzem, S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22) : 2134 - 2146
  • [5] Brutel C., 2014, INSEE PREMIERE
  • [6] Comite Scientifique de l'etude HEPCORT, 1 RES PREV HEP C MED
  • [7] EASL Recommendations on Treatment of Hepatitis C 2016
    European Association for the Study of the Liver easloffice@easloffice.eu
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : 153 - 194
  • [8] European Association for the Study of the Liver, EASL REC TREATM HEP
  • [9] Farhang Zangneh H, 2017, AASLD ANN M 2017 OCT
  • [10] Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
    Foster, G. R.
    Afdhal, N.
    Roberts, S. K.
    Braeu, N.
    Gane, E. J.
    Pianko, S.
    Lawitz, E.
    Thompson, A.
    Shiffman, M. L.
    Cooper, C.
    Towner, W. J.
    Conway, B.
    Ruane, P.
    Bourliere, M.
    Asselah, T.
    Berg, T.
    Zeuzem, S.
    Rosenberg, W.
    Agarwal, K.
    Stedman, C. A. M.
    Mo, H.
    Dvory-Sobol, H.
    Han, L.
    Wang, J.
    McNally, J.
    Osinusi, A.
    Brainard, D. M.
    McHutchison, J. G.
    Mazzotta, F.
    Tran, T. T.
    Gordon, S. C.
    Patel, K.
    Reau, N.
    Mangia, A.
    Sulkowski, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) : 2608 - 2617